基于人群的致病性临床变异外显率研究
这项队列研究纳入BioMe生物样本库和英国生物样本库共72434名参与者,评估已知疾病易感基因中临床变异的人群疾病风险。5360个致病性/功能丧失变异中4795个(89%)的风险差≤0.05,致病性变异平均外显率为6.9%,良性变异为0.85%,外显率总体可变但普遍较低,需进一步研究以完善变异解读和临床评估。
要点
- 在72434名参与者中,89%的致病性/功能丧失变异风险差≤0.05。
- 致病性变异平均外显率6.9%,良性变异0.85%,差值6.0个百分点。
- 外显率随年龄修饰,70岁及以上为10.3%,20岁及以上为8.5%。
核心结论
- 在2个大型生物样本库队列中,致病性/功能丧失变异的估计外显率可变但普遍较低。
- 需要进一步开展基于人群的外显率研究,以完善变异解读和携带这些变异等位基因个体的临床评估。
研究设计与样本
- 这项队列研究纳入BioMe生物样本库自2007年起入组、随访至2020年12月的个体,以及英国生物样本库2006至2010年入组、随访至2020年6月的个体。
- 共纳入72434名参与者,携带37780个临床变异;参与者有外显子组和电子健康记录链接数据,年龄大于20岁,祖先背景多样。
- 英国生物样本库43395人(平均[SD]年龄57[8.0]岁;24065[55%]女性;2948[7%]非欧洲裔),BioMe生物样本库29039人(平均[SD]年龄56[16]岁;17355[60%]女性;19663[68%]非欧洲裔)。
- 暴露为既往报告为致病性或经生物信息学算法预测导致蛋白质功能丧失的变异(致病性/功能丧失变异)。
- 主要结局为临床变异相关的疾病风险,测量携带变异等位基因个体(外显率)与携带正常等位基因个体之间疾病患病率的风险差(RD)。
主要发现
- 5360个致病性/功能丧失变异中,4795个(89%)的风险差小于或等于0.05。
- 致病性变异平均外显率为6.9%(95%CI,6.0%-7.8%),ClinVar报告的良性变异为0.85%(95%CI,0.76%-0.95%),差值6.0(95%CI,5.6-6.4)个百分点;两组中位数均为0%,因大量变异无外显。
- 晚发型疾病的致病性/功能丧失变异外显率受年龄修饰:70岁及以上个体平均外显率10.3%(95%CI,9.0%-11.6%),20岁及以上个体8.5%(95%CI,7.9%-9.1%),差值1.8(95%CI,0.40-3.3)个百分点。
- 致病性/功能丧失变异的外显率即使在已知疾病易感基因中也呈异质性,包括BRCA1(平均[范围],38%[0%-100%])、BRCA2(平均[范围],38%[0%-100%])和PALB2(平均[范围],26%[0%-100%])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步开展基于人群的外显率研究,以完善变异解读和携带这些变异等位基因个体的临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Population-based assessment of disease risk associated with gene variants informs clinical decisions and risk stratification approaches. OBJECTIVE: To evaluate the population-based disease risk of clinical variants in known disease predisposition genes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 72 434 individuals with 37 780 clinical variants who were enrolled in the BioMe Biobank from 2007 onwards with follow-up until December 2020 and the UK Biobank from 2006 to 2010 with follow-up until June 2020. Participants had linked exome and electronic health record data, were older than 20 years, and were of diverse ancestral backgrounds. EXPOSURES: Variants previously reported as pathogenic or predicted to cause a loss of protein function by bioinformatic algorithms (pathogenic/loss-of-function variants). MAIN OUTCOMES AND MEASURES: The primary outcome was the disease risk associated with clinical variants. The risk difference (RD) between the prevalence of disease in individuals with a variant allele (penetrance) vs in individuals with a normal allele was measured. RESULTS: Among 72 434 study participants, 43 395 were from the UK Biobank (mean [SD] age, 57 [8.0] years; 24 065 [55%] women; 2948 [7%] non-European) and 29 039 were from the BioMe Biobank (mean [SD] age, 56 [16] years; 17 355 [60%] women; 19 663 [68%] non-European). Of 5360 pathogenic/loss-of-function variants, 4795 (89%) were associated with an RD less than or equal to 0.05. Mean penetrance was 6.9% (95% CI, 6.0%-7.8%) for pathogenic variants and 0.85% (95% CI, 0.76%-0.95%) for benign variants reported in ClinVar (difference, 6.0 [95% CI, 5.6-6.4] percentage points), with a median of 0% for both groups due to large numbers of nonpenetrant variants. Penetrance of pathogenic/loss-of-function variants for late-onset diseases was modified by age: mean penetrance was 10.3% (95% CI, 9.0%-11.6%) in individuals 70 years or older and 8.5% (95% CI, 7.9%-9.1%) in individuals 20 years or older (difference, 1.8 [95% CI, 0.40-3.3] percentage points). Penetrance of pathogenic/loss-of-function variants was heterogeneous even in known disease predisposition genes, including BRCA1 (mean [range], 38% [0%-100%]), BRCA2 (mean [range], 38% [0%-100%]), and PALB2 (mean [range], 26% [0%-100%]). CONCLUSIONS AND RELEVANCE: In 2 large biobank cohorts, the estimated penetrance of pathogenic/loss-of-function variants was variable but generally low. Further research of population-based penetrance is needed to refine variant interpretation and clinical evaluation of individuals with these variant alleles.
引用
- Forrest IS, Chaudhary K, Vy HMT, et al. Population-Based Penetrance of Deleterious Clinical Variants. JAMA. 2022. PMID: 35076666. doi:10.1001/jama.2021.23686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。